Bladder cancer is the fourth most incident cancer in males and ninth most in females. In the United States, over 67,000 new cases are diagnosed per year, and over 350,000 1 cases diagnosed worldwide. Men have a higher risk of bladder cancer than women transitional cell carcinoma (3:1). Urothelium cancers account for 5.6% of male and 1.8% of female cancers in India, with actual crude rate incidence of 2 about 1 in 174 and 1 in 561 women, respectively. We conducted a detailed study of the bladder cancer cases registered from 2005 to 2010 in the only tertiary care hospital in India. This study revealed that bladder cancer ranks as the 7th leading cancer and accounts for 5.9% of all prevalent cancers in the Kashmiri population (data accepted).
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Bladder cancer arises primarily from transitional cells of the bladder mucosal epithelium (90% of cases) and may present as a noninvasive, papillary tumor protruding from the mucosal surface, which is readily resectable. This stark difference in morphology and survival implicates separate oncogenic pathways for noninvasive compared to muscle- 3, 4 invasive cancer. The incidence of bladder cancer was strongly associated with occupational exposure to aromatic amines used in the dye industry, before their potent cell carcinoma (TCC) of the bladder, except for 1 case of adenocarcinoma. A recurrence was defined as the presence of histologically proven bladder cancer at a positive cystoscopy after a complete previous resection. Venous blood (3-5 ml) was collected from each patient in ethylene diamine tetra acetic acid (EDTA) as a control, to rule out any germ line mutation.
DNA extraction
Samples of both the tumor and adjacent normal tissue were collected. Samples were snap-frozen immediately and stored at -80°C. DNA from both types of tissue was extracted using DNeasy Blood and Tissue Kit (Qiagen GmbH; Hilden, Germany), according to the manufacturer's enclosed protocol.
Polymerase chain reaction (PCR)
Exons 1 and 2 of the RAS genes containing hotspot carcinogenicity to the bladder was demonstrated. With reduction of such workplace exposure, active smoking is now the strongest environmental risk for bladder cancer, 4, 5 contributing to more than 50% of cases. The four cellular RAS genes encode four highly homologous 21 kDa proteins: HRAS, NRAS, KRAS4A and KRAS4B. Activating Ras mutations occur in ~30% of human 5 cancers. H-RAS mutations predominate in bladder cancer. Activating RAS mutations occur in ~30% of human cancers. Specific RAS genes are mutated in different malignancies: KRAS mutations are prevalent in pancreatic, colorectal, endometrial, biliary tract, lung and cervical cancers; KRAS and NRAS mutations are found in myeloid malignancies; and NRAS and HRAS mutations predominate in melanoma 6 and bladder cancer, respectively. In most cases including bladder cancer, the somatic missense RAS mutations found in cancer cells introduces amino acid substitutions at positions 12, 13 and 61. These changes impair the intrinsic GTPase activity and confer resistance to GAPs, thereby causing cancer associated mutant Ras proteins to accumulate 7 in the active, GTP bound conformation. The threedimensional structure of H-ras bound to the catalytic domain of p120 GAP, known as the GAP-related domain, has been solved and provides a structural understanding of the 7 biochemical activation of oncogenic Ras proteins.
To date a comprehensive analysis of all three RAS genes has not been carried out in a large series of bladder tumors. Therefore, the aim of our study was to assess the contribution of H-ras gene mutations to the incidence and/or development of transitional cell carcinoma of urinary bladder in patients from the Kashmir valley, as no such study has been reported from this region.
Methods

Study Design
This prospective study was conducted at the Sher-iKashmir Institute of Medical Sciences (SKIMS) in Kashmir, India, between 2008 and 2010. The Medical Ethical Committee of SKIMS Deemed University approved the study. All patients signed the written informed consent.
A total of 65 consecutive patients in the urological surgery department who underwent transurethral resection of bladder tumors (TURBT) and radical prostatocystectomy were included in this study. Their median age at the time of diagnosis was 61 years (range, 38-80 years); the male: female ratio was 5:1 (Table 1) . Fifty patients (76.9 %) were smokers and 15 (23.1%) were nonsmokers. The majority of patients (70%) lived in a rural environment. Almost all patients presented with hematuria. Information on tumor grade and stage was obtained for all patients. The diagnostic slides were reviewed by a panel of 2 expert pathologists to confirm the diagnosis and ensure uniformity of classification criteria. All of the samples resected by the urological surgeon were histologically proven transitional codons 12, 13, and 61 were amplified using the previously described specific primers (Table 2) PCR amplification was carried out in a 50 µL volume containing 50 ng of genomic DNA, 1X PCR buffer containing 15mM MgCl , 100 µM 2 each of dATP, dGTP, dTTP and dCTP, 1.5U of Taq DNA polymerase (Biotool, Spain), and 1 µM of forward and reverse primers. After an initial denaturation at 95°C for 5 min, 35 cycles at 94°C for 1 min, a specific annealing temperature (Table 2 ) for 1 min, and 72°C for 1 min were performed. PCR products were run on 2% agarose gel and analyzed undera UV illuminator. Single-strand conformation polymorphism (SSCP) analysis of the amplicons of exon 1 and 2 of RAS was performed on 6% non denaturing polyacrylamide gel (PAGE) utilizing a non-radioactive silver 12 staining procedure. The purified PCR amplicons of the tumor samples showing mobility shift on SSCP analysis were confirmed by direct sequencing (Figures 1). In order to rule out germ line mutation, DNA from the blood samples of the patients showing mutations were subjected to direct DNA sequencing, using the automated DNA sequencer ABI prism 310.
For statistical analysis of the data, the chi-square test was used to evaluate the association between clinicpathological variables. p values <0.05 were considered significant.
Results
Screening of RAS genes was conducted in a series of 65 bladder cancer samples. The mutations were found only seen in the two hot spot codons (12 and 61) of RAS and all the mutations that were identified in this study were of missense nature. The overall mutations in exon 1 and 2 of all the forms of RAS genes including HRAS, NRAS and KRAS identified in this study aggregated to 21.5% (14 of 65).These mutations were found in HRAS and NRAS only whereas no mutation was detected in KRAS and the representative partial five were G:C > T:A transversions, three were A: T > T: A transversions. No significant association was found between tumor grade or stage and mutation was apparent (p>0.72 for each) ( Table 3 ). The 14 tumor samples with mutation included one G-I, six G-II, five G-III and two G-IV tumors, four pTa, four pT1 and six pT2 tumors. There was no significant association between distribution of RAS gene mutation with any other clinic-pathological parameters (p>0.05) ( Table 4) . The mutations in exon 1 and 2 of HRAS identified in this study aggregated to 13.8% (09/65). In all, there were nine mutations (3 transitions and 6 transversions), four were A:T>G:C transitions, three G:C>T:A transversions, and two A:T>T:A transversions, out of which three mutations affected codons 12 (33.3%) and six mutations affected codon 61 (66.6%) ( Table 3) . No mutation was detected in codon 13 in this study. Among these samples harboring mutations, there were four Q61R (CAG>CGG), three G12C (GGC>TGC) and two Q61L (CAG>CTG). Among all 09 mutations detected, the majority of HRAS mutations were similar base pair transitions, occurring predominantly at the second bases of codons 61 (A>G)( Table 3 ).The pattern and distribution when stratified for HRAS mutations was found to be significantly associated with smoking (p<0.05) ( Table 4) .
The total mutations in exon 1 and 2 of NRAS gene detected in this study were 7.7% (5/65). There were five mutations (2 transitions and 3 transversions); two were A:T>G:C transitions, two G:C>T:A transversions, and one A:T>T:A transversion, out of which two affected codons 12(40%) and three affected codon 61(60%)(Table1). No mutation was detected in codon 13 in this study. The samples harboring mutations had two G61C (GGT>TGT), two Q12R (CAA>CGA), and one Q61L (CAA>CTA) ( Table 3 ).
The mutations were mostly seen in smokers (14/65) and one mutation was detected in bladder tumor of a non smoker. No mutation was detected in KRAS in all the 65 samples. The matched constitutional DNA (Blood Cell DNA) contained the wild-type sequence for RAS genes in every case, demonstrating the somatic nature of these mutations in bladder cancer.
The overall pattern of mutations identified in RAS gene family were statistically non-significant with smoking status (p>0.05) ( Table 4) .
Discussion
In the present research study, mutational spectrum of RAS genes including HRAS, NRAS and KRAS (exon 1 & 2) were studied in 65 confirmed bladder tumors (64 TCC and one adenocarcinoma). Studies on a variety of tumors have demonstrated some "hot spots" in RAS gene family that are susceptible to point mutations. Many studies have detected [8] [9] [10] different types of RAS mutations in human bladder tumors but all three RAS gene family members have been seldom screened for mutation in the same sample series in UBC. Thus an aim of this study was to carry out comprehensive mutational screening of all three RAS genes in a series of UBC samples.
The four cellular RAS genes encode four highly homologous 21 kDa proteins: HRAS, NRAS, and KRAS. Activating RAS mutations occur in ~30% of human cancers The HRAS mutation was first detected in the human bladder of urine sediments from bladder cancer patients , Czerniak et al observed HRAS mutation specifically in connection to 14 codon 12 in 45% of the bladder cancers. The mutational frequency observed in our study 14 of 13, 15 65(21.5%) is consistent with most of the earlier studies. Also in a recent study by Jebar et al(2005) on 98 bladder tumors and 31 bladder cell lines, RAS mutation was detected in 13% of both types of samples18. In total, there were 10 mutations in HRAS (4 in codon 61 and 2 each in codon 12 and 13), 4 in KRAS, and 4 in NRAS which is in accordance with our study except lack of any mutation in KRAS found in our tumor series. The observed discrepancies in the mutation pattern of RAS gene family among different populations suffering from bladder cancer may either reflect different etiological mechanisms involved in disease progression or alternative RAS dysfunction such as gene amplification 16, 17 and/or overexpression.
All the mutations that were identified in HRAS in this study were of missence nature. The rate of transversions (66.7%) was found to be higher than the transition (33.3%). Based on previous studies, it was expected that codon 12 mutations would predominate but this was not the case in this study. Six mutations in codon 61 and only three mutations in codon 12 were identified. No mutation was detected in codon 13 in this study. Most of the mutations found in HRAS in human tumors involve these two codons, coding for glycine and glutamine residues, which play an important role in the catalytic site of RAS gene. These substitutions alter its GTPase activity to a different extent and/or its ability to interact with its regulators, depending upon the substituted amino-acid residue. It was also predicted that the most frequent substitution in codon 12 would be G>A at the second position (Val), but this mutation was not detected in any tumors.
Further, mutations in HRAS detected in this study were diverse comprising nine mutations, four were A>G transitions, three G>T transversions, and two A>T transversions Among these samples harboring mutations, there were four Q61R (CAG>CGG), three G12C (GGC> TGC) and two Q61L (CAG>CTG) transversions (three G: C >T: A and one A: T>T: A) and three transitions (A: T>G: C). A similar spectrum of substitutions is characteristic of transitions only in smokers. Similar pattern of mutation was identified in this study which is consistent with above data with almost all mutations in conformation with three G:C>T:A and three A:T>G:C correlating with smoking status. Interestingly in our study all these mutations were traced in male subjects which were ever smokers except one former smoker and mutation pattern showed a significant association with smoking (p<0.05). As Kashmir is not an industrialized region, the exposure of the chemicals is rare particularly aromatic (aryl)-amines such as naphthalene, benzidine, aniline dyes, and 4-aminobiphenyl which are 22 known bladder carcinogens. With moderate reduction of such workplace exposure, active smoking seems the strongest environmental risk contributing to all bladder cancer cases in Kashmiri population in this study. In Kashmir, besides cigarette smoking, hookah smoking (smoking through water filter) is also a popular form. However smoking is mostly practiced by males and women are seldom involved in this practice. Thus the present study confirmed the hypothesis that HRAS plays an important role in bladder tumorigenesis and in this regard authors present study of HRAS mutational 23 analysis has been published.
The 'hot spot' mutation at codon 12, 13 or 61 in the NRAS gene has been described in many kinds of human 24 cancers. Though our study found relatively low frequency of specific NRAS mutations but it confirms the role in the development of urinary bladder carcinoma, as we detected 7.6% tumors harboring NRAS mutations (5/65 tumors) having mutations in this gene. Out of these 60% were in codon 61, 40% in codon 12 and like HRAS no mutation was detected in codon 13. All of the mutations that were identified in this study were missense with a rate of transversions as 60% and transitions 40%. Three mutations in codon 61 and two in codon 12 were identified and the predominance of these mutations was expected, as most of the mutations found in NRAS in human tumors involve 15 these two codons consistent with previous study. The mutations detected in this study comprised three transversions (two G: C>T: A and one A: T>T: A) and two transitions (A: T>G:C). A similar spectrum of substitutions 18 is characteristic of TP53 mutations in bladder tumors. This may reflect the known association of increased bladder 19 cancer risk with cigarette smoking. Five of the mutations in NRAS gene were detected in males who were ever smokers and one mutation was seen in an elderly non smoker female and but were found to be statistically insignificant (p>0.05).
No sequenced mutations of NRAS have been described previously in bladder cancer except one recent study where mutations found in NRAS were G12R, Q61L and Q61R. In other tumor types where NRAS mutation is found (e.g., haematopoietic, laryngeal and skin cancers), codon 61 is most commonly mutated, and Q61R is the most common mutation (http://www.sanger.ac.uk/ perl/CGP/cosmic). Interestingly, only nine of the 1132 mutations of NRAS recorded are G12R. Therefore, it will be important to analyze more bladder tumors to determine whether this is a chance finding or whether there may be some tissue specificity in the mutation spectrum.
Several studies have examined KRAS in bladder tumors [25] [26] [27] and only a few have been reported mutations. We found no mutation in KRAS suggesting the involvement of KRAS a very rare and infrequent event in UBC.
The RAS family member involves specificity in other tumor types that is most commonly activated. For example, most colorectal cancers show KRAS mutation while hematological malignancies show predominantly NRAS mutation. Overall, the vast majority of mutations in human cancers are found in KRAS2 and mutations in HRAS are relatively rare. The exact reasons for this specificity are not yet clear but some recent studies point to possible differences in the ability of different Ras proteins to activate different Raf 28 isoforms. Whatever the explanation for the differences, it appears that either some shared function of all three RAS genes is important in UBC cells or that any of the potentially different biological effects can contributes to UBC development.
RAS gene mutations do not seem to be associated with 15 stage or grade. RAS genes are mutated in some invasive UBCs and there is no clear association with invasive rather than superficial disease. In vitro experiments on human tumor cells indicate that HRAS can up regulate EGFR expression and induce an invasive phenotype. However, in transgenic mice engineered to express mutant HRAS leads to the development of superficial papillary tumors. In this study we could not detect any significant correlation of RAS gene mutation with different grades and stages of bladder cancer either between superficial or invasive cancer which is in clear agreement with published data. Low grade cases(G-I & II) were reported harboring 50% mutations and high grade cases contained around 35.7% in G-III and 14.3% in G-IV while as 42.9% mutations were found in high stage disease (pT2) and 57.1% each in low stage (pTa and pT1). This even distribution of mutations implicates that RAS gene mutation is involved through the early event to late stage disease progression which needs to be evaluated by taking a large cohort of samples.
Although diet might also influence bladder carcinogenesis owing to the presence of many potential carcinogens (nitroso compounds) in the customary dietary items of Kashmir, no consistent association between intake of selected nutrients or micronutrients and RAS positive cases has emerged in this study. Further no association with the age, location of tumor, and/or its size was found with the distribution of mutations in RAS genes.
